Hypoparathyroidism Treatment Market
Market Insights on Hypoparathyroidism Treatment covering sales outlook, demand forecast & up-to-date key trends
Hypoparathyroidism Treatment Market by Product Type (Parathyroid Hormone, Vitamin D Analogue, Calcium Supplements), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales) & Region - Forecast to 2021-2031
About the Report
Parathyroid hormone (PTH) plays a pivotal role in maintaining the optimum level of calcium, phosphate and calcitriol (active Vitamin D) in the blood and bones. Hypoparathyroidism, is an uncommon endocrine disorder that develops due to low production or absence of parathyroid hormone.
Globally, hypoparathyroidism affects approximately 200, 000 people, out which most cases are associated with accidental damage or removal of the parathyroid gland during thyroid surgery. Other cases are associated to autoimmune, hereditary, and idiopathic issues. The current standard treatment involves use of calcium and vitamin D analogues (Vitamin D2 & Vitamin D3).
On the other hand, hormonal therapy is also gaining attention, where the primary treatment has found success in cases of severe hypoparathyroidism. The side effects include potential risks associated with developing osteosarcoma has limited adoption rates. However, manufacturers in the market are focusing on investing significantly in the development of safe, and effective hormonal therapies in long-term strategies.
In its new study, ESOMAR certified research firm, Future Market Insights offers details about key driving factors in the market. The report also tracks the global sales of the hypoparathyroidism drugs in more than 10+ high growth markets, along with an analysis of the impact of the COVID-19 pandemic in terms of orphan drugs and rare disease treatments.
Let us know your requirement to get
100% FREE customization
How Does the Future Outlook for Hypoparathyroidism Treatment Market Compare to Historical Data?
Between 2016 and 2020, the demand for calcium supplements for treating hypoparathyroidism, dominated the global market mainly owing to cost and efficacy benefits over hormonal therapies and other drugs. Subsequently, rising research and development activities supported market growth.
NATPARA (Takeda), and Rocaltrol (Roche) are some of the commonly prescribed drugs to treat moderate to severe hypoparathyroidism. However, issues of product recall and the resultant mismanagement in treatments has led to hospitalizations in severe cases. Manufacturers such as Ascendis Pharma A/S, EnteraBio Ltd, ProLynx, Inc. and Extend Biosciences, Inc. have hormonal therapies in pipeline which have delivered superior patient outcomes.
The COVID-19 has impacted the healthcare sector severely. While, clinical trials for the rare diseases are halted/postponed through 2020 due to priority given to the development of lifesaving drugs, the market for hypoparathyroidism is expected to witness a short-term slump even through 2021.
However, government support in the form of funding and grants to support the development of new hormonal therapy, the relaxation of lockdown regulations is expected to provide numerous opportunities for market growth. As a result, the market is expected to grow at a steady pace during the forecast period.
Additionally, the market is expected to witness an increase in patient screening for a number of thyroid conditions owing to growing patient awareness. Moreover, the approval and designation of hypothyroidism drugs as orphan products by U.S. FDA and the European Commission (EC), coupled with the untapped patient population is expected to have a positive impetus on market growth.
Emergence of personalized medicines, the rapid rise in demand for biologics for hypothyroidism, and consolidation activities by market players will create significant opportunities for the expansion of hypothyroidism treatment market size over the forecast period, which is projected to expand at a CAGR close to 8% through 2031.
How are Changes in Reimbursement Policies Fueling Market Growth?
Government support in terms of receiving an orphan drug designation from regulatory bodies such as the U.S. FDA and European Commission (EC) and financial and tax incentive factors are expected to result in high return on investment for companies developing novel drugs for treating hypoparathyroidism.
The U.S. FDA’s orphan drug status is given to biologics affecting fewer than 200,000 people in the U.S. alone with benefits of various incentives including tax incentives for qualified clinical trials and market exclusiveness on receiving regulatory approval.
For hypoparathyroidism, NATPARA is the only drug issued with a black box warning, which was notified by U.S. FDA, in January 2015, which is currently has exclusivity until 2022. Also, the treatment is covered by a number of insurance companies and co-pay policies. Such initiatives are expected to boost the production of novel drugs, which is expected to positively influence growth of the market in near future.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhy are Labelling Restrictions on NATPARA Limiting Market Growth?
Currently, NATPARA is only available drug to treat hypoparathyroidism. Because of its side effects including a potential risk of osteosarcoma, high blood calcium levels, and reduced sense of touch or pain sensation in joints, which could result in hospitalization. The drug is only made available through NAPTARA Risk Evaluation and Mitigation Strategy (REMS) Programs.
Hence, in most of the cases oral medications are considered as standard treatment for hypoparathyroidism. This limits the adoption of available hormonal therapy. Further, long-term beneficial drug usage symptoms have still not been demonstrated across clinical trials, which might limit the adoption of therapy in patients given the high price of the injection. Drug literature review 2018 states that therapy with rhPTH (1-84) is a long-term management option, where more long-term efficacy and safety data are needed in humans.
Also, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for NATPARA in lieu of these side effects. Thus, labelling restrictions are expected to hold back the penetration of NATPARA in the major global markets, thereby hampering the overall growth of the market.
How are Small Molecule Biologics Creating Growth Opportunities?
The hypoparathyroidism treatment market is shifting towards the demand for biologics over conventional drug alternatives. The efficacy of biologics and their ability to mimic natural body hormones is greater as compared to small molecule options in conventional therapy. This benefit is an essential influencing factor driving the demand for biologics.
Furthermore, biologics promote conversion of vitamin D into active forms, which increases the absorption of oral calcium supplements, resulting into synergies with conventional calcium in supplement therapy. Considering the aforementioned factors, the emergence of biologics is expected to offer lucrative opportunities for the growth of hypothyroidism treatment market.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Country-wise Insights
What are the Prospects of Adoption for Hypoparathyroidism Treatments in the U.S.?
NATPARA (parathyroid hormone), is a recombinant hormonal therapy approved in the United States for the treatment of hypoparathyroidism. It is prescribed to the patients who do not show positive results from standard therapies including calcium supplements and vitamin D.
In September 2019, Takeda Pharmaceutical Company Limited, announced the recall for all its doses of NATPARA injections in the U.S. This recall was attributed to presence of small rubber particles in solution samples, which originated from the rubber septum of the NATPARA cartridge.
This recall of injectable PTH in the U.S. has created distress among the patients and had a significant impact on treatment cycles. Around 2,700 patients have been affected by shortage. Patients who are currently being treated with the therapy, have been pushed back to oral medications including calcium supplements and activated vitamins D to control their symptoms.
This transition has created a negative impact on the disease management, with leading some patients to hospitalization because of the severe hypocalcemia. Further, manufacturers anticipates that the PTH injectable will require another year to return back to the market.
Why is Germany a leading the Europe Hypoparathyroidism Treatment Market?
Factors such as rising occurrences of parathyroid diseases, rising government initiatives, increasing medical care expenditure, better regulatory scenario, and rising reimbursement policies and funding are persistently aiding the expansion of the hypoparathyroidism treatment market in Germany. As indicated by the information proposed by Eurostat, it is seen that among the EU Member States, the largest share of medical care expenditure was recorded in Germany in 2019.
Further, growing approvals and orphan drug designation from European commission (EC), increasing candidates in clinical trials for development of hormonal therapy, presence of pharmaceutical players, which leads to better availability or products across the continent, are some of the factors that are responsible for making Germany, one of the largest market for hypoparathyroidism in Europe.
How Are Government Initiatives Boosting Hypoparathyroidism Treatment market in India?
Implementation of government programs aimed at offering affordable and quality healthcare is expected to complement growth of India's biopharma industry, in turn creating opportunities for hypoparathyroidism treatment market. Increasing adoption of technologically advanced treatment and rising awareness among people in India is fuelling the demand for hypoparathyroidism treatment.
Moreover, India is also considered as one of the top destinations of thyroid related disorders in the world, increasing the need for Hypoparathyroidism Treatment market in the region. Increasing patient pool due to rise in population, emergence of new diseases, and lifestyle changes are also boosting demand for biopharmaceuticals, which is expected to provide high opportunity for providers of hypoparathyroidism treatment.
Category-wise Insights
How are Calcium Supplements Contributing to Market Revenue?
Hypoparathyroidism is characterised by low parathyroid hormone secretions which results in low calcium levels in the body. Calcium supplements are preferred as the first line of treatment by doctors in order to normalise the deficiency.
Also, these supplements show a reduced risk of side effects as compared to hormonal therapy. Moreover, the recent U.S. recall of the NATPARA had compelled patients to opt for oral medication such as calcium supplements to treat the symptoms. These factors will drive demand for calcium supplements, accounting for the largest share in the global market.
Which is the Preferred Route of Administration for Hypoparathyroidism Treatment ?
The oral segment by route of administration, held the highest market share due to rising product launches and the presence of a solid pipeline. Various factors like a rapid delivery of drugs, high efficacy, and a higher rate of bioavailability are projected to impel the oral segment development. For drugs having medium to high oral availability, the oral route of administration is effective.
Oral treatments limit the utilization of central lines for intravenous drug administration and accordingly decrease the danger of complications related with it and also a hospital stay. The advancement of promising new medications and potential clinical pipeline applicants are a portion of the major factors expected to boost segment development.
What is the share of hospital & retail sales in global Hypoparathyroidism Market?
The hospital and retail sales is expected to show maximum share in the market among all distribution channels due to increasing number of facilities and easy accessibility to patients. Also, the quick delivery of medicines is one of the major factors driving the market growth during the forecast period. As there are rising number of cases of hypoparathyroidism, there is increasing demand for faster accessibility and availability of medicine to treat the disorders as rapid as possible. Thus, hospitals and retail providers are able to provide medicines to the patients at faster rate and in turn increases the hypoparathyroidism treatment market.
Competitive Landscape
The global hypoparathyroidism treatment market is dominated by top manufacturers -Takeda Pharmaceutical Company Limited., Entera Bio Ltd., F. Hoffmann-La Roche Ltd, Amgen Inc., and Ascendis Pharma A/S Manufacturers are focusing on enhancing their global and regional presence through acquisitions and collaboration strategies.
- For instance, in January 2019, Takeda Pharmaceutical Company acquired Shire plc. With this Acquisition, Takeda strengthened its geographic presence in the U.S., which is one of the key markets for biopharmaceuticals. Also, the acquisition of Shire has strengthened Takeda’s product portfolio and provides it a leading position in GI, neuroscience, rare diseases, oncology and PDT.
- Ascendis Pharma established VISEN Pharmaceuticals, in November 2018, collaborated to develop, manufacture, and commercialize company’s TransCon Endocrinology Rare disease therapies in Greater China. This includes, mainland China, Hong Kong, Macau, and Taiwan. Such collaborations are anticipated to expand TransCon PTH’s reach in Asian economies.
- In March 2021, BridgeBio Pharma announced positive outcomes from its 2nd stage trial of its new drug encaleret. As a part of hypoparathyroidism treatments, the drug has show effectiveness among patients with autosomal dominant hypocalcemia type 1.
Some of the leading companies operating in the market are:
- Takeda Pharmaceutical Company Limited.
- Entera Bio Ltd.
- Amgen Inc.
- Ascendis Pharma A/S
- F. Hoffmann-La Roche Ltd
- ProLynx, Inc.
- Extend Biosciences, Inc.
- BionPharma Inc.
* The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of Report
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
USD Million for Value |
|
Key Regions Covered |
North America, Latin America, Europe, Asia Pacific and the Middle East & Africa |
|
Key Countries Covered |
U.S., Canada, Brazil, Mexico, Germany, U.K., France, Italy, Spain, China, India, Japan, Australia &, New Zealand, South Africa, and GCC Countries |
|
Key Segments Covered |
Product Type, Route of Administration Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
|
Customization & Pricing |
Hypoparathyroidism Treatment Market
By Product Type
- Parathyroid Hormone
- Natpara
- Others
- Vitamin D Analogue
- Vitamin D2
- Vitamin D3
- Calcium Supplements
By Route of Administration
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
Region
- North America
- Latin America
- Europe
- Asia Pacific MEA
Frequently Asked Questions
The U.S. currently leads the global market for hypoparathyroidism treatment, and demand will be significant throughout the forecast period. Growing number thoracic surgeries, and high prevalence of hypoparathyroidism are some of the key factors contributing to the higher demand.
Vitamin D analogue for vitamin D analogue (vitamin D2&D3) hold significant share in the hypoparathyroidism treatment market. The demand is expected to remain high in the near future, especially due to preference among physician as a first line of treatment owing to its convenience of oral administration.
Some of the prominent players offering drugs for hypoparathyroidism include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, ProLynx Inc, Amgen, Inc. EnteraBio Ltd, and Ascendis Pharma A/S
Limited availability of hormonal therapy (NATPARA) due to adverse side effects is the key restraint for market growth. Apart from this high treatment cost and product recalls are some the factors having negative impact on the market growth.
The COVID-19 pandemic resulted in a significant drop in the demand for hypoparathyroidism care. Furthermore, clinical studies have been put on hold temporarily in order to focus on developing a potential drug to tackle the coronavirus. However, with the availability of the COVID-19 vaccines, the clinical trials are resuming for development of drug candidates, the market is expected to recover in the long-term.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, Key Regions & Countries
4.2. Pipeline Assessment
4.3. Brand Analysis -Natpara
4.4. Key Market deals
4.5. Regulatory scenario
4.6. Key Promotional Strategies, By Manufacturers
5. Global Hypoparathyroidism Treatment Market Demand (Size in US$ Mn) Analysis 2016-2020and Forecast, 2021-2031
5.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
5.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Per Capita Healthcare Expenditure Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Significant Patient Pool for Hypoparathyroidism
6.2.2. Growing Prevalence of Thoracic Surgeries ad Thyroid Cancer
6.2.3. Increasing number of Clinical Trials
6.2.4. Approval of Orphan Drug Status
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. COVID19 Crisis Analysis
7.1.1. Current COVID19 Statistics and Probable Future Impact
7.1.2. Current GDP Projection and Probable Impact
7.1.3. Current Economic Projection as compared to 2008 Economic analysis
7.1.4. COVID19 and Impact Analysis
7.1.4.1. Revenue By Product Type
7.1.4.2. Revenue By Route of Administration
7.1.4.3. Revenue By Distribution Channel
7.1.4.4. Revenue By Country
7.1.5. 2020 Market Scenario
7.1.6. Quarter by Quarter Forecast
7.1.7. Projected recovery Quarter
7.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact
8. Global Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2016–2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2021-2031
8.3.1. Parathyroid Hormone
8.3.1.1. Natpara
8.3.1.2. Others
8.3.2. Vitamin D Analogue
8.3.2.1. Vitamin D2
8.3.2.2. Vitamin D3
8.3.3. Calcium Supplements
8.4. Market Attractiveness Analysis By Product Type
9. Global Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2016–2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2021-2031
9.3.1. Oral
9.3.2. Parenteral
9.4. Market Attractiveness Analysis by Route of Administration
10. Global Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016–2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Sales
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Product Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By Route of Administration
12.4.4. By Distribution Channel
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Latin America Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Rest of Latin America
13.3.2. By Product Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By Route of Administration
13.4.4. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Europe Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. U.K.
14.3.1.3. France
14.3.1.4. Italy
14.3.1.5. Spain
14.3.1.6. Rest of Europe
14.3.2. By Product Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By Route of Administration
14.4.4. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Asia Pacific Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. China
15.3.1.2. India
15.3.1.3. Japan
15.3.1.4. Australia & New Zealand
15.3.1.5. Rest of Asia Pacific
15.3.2. By Product Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By Route of Administration
15.4.4. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Middle East and Africa Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. South Africa
16.3.1.3. Rest of Middle East and Africa
16.3.2. By Product Type
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By Route of Administration
16.4.4. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Key and Emerging Countries Hypoparathyroidism Treatment Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. U.S. Hypoparathyroidism Treatment Market Analysis
17.2.1.1. By Product Type
17.2.1.2. By Route of Administration
17.2.1.3. By Distribution Channel
17.3. Canada Hypoparathyroidism Treatment Market Analysis
17.3.1.1. By Product Type
17.3.1.2. By Route of Administration
17.3.1.3. By Distribution Channel
17.4. Mexico Hypoparathyroidism Treatment Market Analysis
17.4.1.1. By Product Type
17.4.1.2. By Route of Administration
17.4.1.3. By Distribution Channel
17.5. Brazil Hypoparathyroidism Treatment Market Analysis
17.5.1.1. By Product Type
17.5.1.2. By Route of Administration
17.5.1.3. By Distribution Channel
17.6. U.K. Hypoparathyroidism Treatment Market Analysis
17.6.1.1. By Product Type
17.6.1.2. By Route of Administration
17.6.1.3. By Distribution Channel
17.7. Germany Hypoparathyroidism Treatment Market Analysis
17.7.1.1. By Product Type
17.7.1.2. By Route of Administration
17.7.1.3. By Distribution Channel
17.8. France Hypoparathyroidism Treatment Market Analysis
17.8.1.1. By Product Type
17.8.1.2. By Route of Administration
17.8.1.3. By Distribution Channel
17.9. Italy Hypoparathyroidism Treatment Market Analysis
17.9.1. By Product Type
17.9.2. Route of Administration
17.9.3. By Distribution Channel
17.10. Spain Hypoparathyroidism Treatment Market Analysis
17.10.1.1. By Product Type
17.10.1.2. By Route of Administration
17.10.1.3. By Distribution Channel
17.11. China Hypoparathyroidism Treatment Market Analysis
17.11.1.1. By Product Type
17.11.1.2. By Route of Administration
17.11.1.3. By Distribution Channel
17.12. Japan Hypoparathyroidism Treatment Market Analysis
17.12.1.1. By Product Type
17.12.1.2. By Route of Administration
17.12.1.3. By Distribution Channel
17.13. India Hypoparathyroidism Treatment Market Analysis
17.13.1.1. By Product Type
17.13.1.2. By Route of Administration
17.13.1.3. By Distribution Channel
17.14. Australia & New Zealand Hypoparathyroidism Treatment Market Analysis
17.14.1.1. By Product Type
17.14.1.2. By Route of Administration
17.14.1.3. By Distribution Channel
17.15. GCC Countries Hypoparathyroidism Treatment Market Analysis
17.15.1.1. By Product Type
17.15.1.2. By Route of Administration
17.15.1.3. By Distribution Channel
17.16. South Africa Hypoparathyroidism Treatment Market Analysis
17.16.1.1. By Product Type
17.16.1.2. By Route of Administration
17.16.1.3. By Distribution Channel
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Company Share Analysis
18.4. Market Presence Analysis
18.4.1. By Regional footprint of Players
18.4.2. Channel Foot Print by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive (Tentative List)
19.3.1. Takeda Pharmaceutical Company Limited
19.3.1.1. Overview
19.3.1.2. Service Portfolio
19.3.1.3. Profitability by Market Segments (Service/Channel/Region)
19.3.1.4. Sales Footprint
19.3.1.5. Strategy Overview
19.3.1.5.1. Marketing Strategy
19.3.1.5.2. Service Strategy
19.3.1.5.3. Channel Strategy
19.3.2. F. Hoffmann-La Roche Ltd
19.3.2.1. Overview
19.3.2.2. Service Portfolio
19.3.2.3. Profitability by Market Segments (Service/Channel/Region)
19.3.2.4. Sales Footprint
19.3.2.5. Strategy Overview
19.3.2.5.1. Marketing Strategy
19.3.2.5.2. Service Strategy
19.3.2.5.3. Channel Strategy
19.3.3. Amgen, Inc.
19.3.3.1. Overview
19.3.3.2. Service Portfolio
19.3.3.3. Profitability by Market Segments (Service/Channel/Region)
19.3.3.4. Sales Footprint
19.3.3.5. Strategy Overview
19.3.3.5.1. Marketing Strategy
19.3.3.5.2. Service Strategy
19.3.3.5.3. Channel Strategy
19.3.4. Ascendis Pharma A/S
19.3.4.1. Overview
19.3.4.2. Service Portfolio
19.3.4.3. Profitability by Market Segments (Service/Channel/Region)
19.3.4.4. Sales Footprint
19.3.4.5. Strategy Overview
19.3.4.5.1. Marketing Strategy
19.3.4.5.2. Service Strategy
19.3.4.5.3. Channel Strategy
19.3.5. EnteraBio Ltd
19.3.5.1. Overview
19.3.5.2. Service Portfolio
19.3.5.3. Profitability by Market Segments (Service/Channel/Region)
19.3.5.4. Sales Footprint
19.3.5.5. Strategy Overview
19.3.5.5.1. Marketing Strategy
19.3.5.5.2. Service Strategy
19.3.5.5.3. Channel Strategy
19.3.6. ProLynx Inc
19.3.6.1. Overview
19.3.6.2. Service Portfolio
19.3.6.3. Profitability by Market Segments (Service/Channel/Region)
19.3.6.4. Sales Footprint
19.3.6.5. Strategy Overview
19.3.6.5.1. Marketing Strategy
19.3.6.5.2. Service Strategy
19.3.6.5.3. Channel Strategy
19.3.7. Extend Biosciences, Inc
19.3.7.1. Overview
19.3.7.2. Service Portfolio
19.3.7.3. Profitability by Market Segments (Service/Channel/Region)
19.3.7.4. Sales Footprint
19.3.7.5. Strategy Overview
19.3.7.5.1. Marketing Strategy
19.3.7.5.2. Service Strategy
19.3.7.5.3. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Hypoparathyroidism Treatment Market Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 02: Global Hypoparathyroidism Treatment Market Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 03: Global Hypoparathyroidism Treatment Market Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Table 04: Global Hypoparathyroidism Treatment Market Analysis 2016-2020and Forecast 2021–2031, By Region
Table 05: North America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, By Country
Table 06: North America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 07: North America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 08: North America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Table 09: Latin America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, By Country
Table 10: Latin America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 11: Latin America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 12: Latin America Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Table 13: Europe Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, By Country
Table 14: Europe Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 15: Europe Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 16: Europe Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Table 17: Asia Pacific Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, By Country
Table 18: Asia Pacific Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 19: Asia Pacific Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 20: Asia Pacific Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Table 21: Middle East and Africa Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, By Country
Table 22: Middle East and Africa Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Product Type
Table 23: Middle East and Africa Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Route of Administration
Table 24: Middle East and Africa Hypoparathyroidism Treatment Market Value (US$ Mn) Analysis 2016-2020and Forecast 2021–2031, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 02: Global Hypoparathyroidism Treatment Market Forecast & Y-o-Y Growth, 2021–2031
Figure 03: Global Hypoparathyroidism Treatment Market Absolute $ Opportunity (US$ Mn) Analysis, 2020–2031
Figure 04: Global Hypoparathyroidism Treatment Market Y-o-Y Growth (%) Analysis, 2020–2031
Figure 05: Global Hypoparathyroidism Treatment Market Value Share (%) Analysis 2021 & 2031, By Product Type
Figure 06: Global Hypoparathyroidism Treatment Market Y-o-Y Growth (%) Analysis 2019-2030, By Product Type
Figure 07: Global Hypoparathyroidism Treatment Market Attractiveness Analysis 2021–2031, By Product Type
Figure 08: Global Hypoparathyroidism Treatment Market Value Share (%) Analysis 2021 & 2031, By Route of Administration
Figure 09: Global Hypoparathyroidism Treatment Market Y-o-Y Growth (%) Analysis 2019-2030, By Route of Administration
Figure 10: Global Hypoparathyroidism Treatment Market Attractiveness Analysis 2021–2031, By Route of Administration
Figure 11: Global Hypoparathyroidism Treatment Market Value Share (%) Analysis 2021 & 2031, By Distribution Channel
Figure 12: Global Hypoparathyroidism Treatment Market Y-o-Y Growth (%) Analysis 2019-2030, By Distribution Channel
Figure 13: Global Hypoparathyroidism Treatment Market Attractiveness Analysis 2021–2031, By Distribution Channel
Figure 14: Global Hypoparathyroidism Treatment Market Value Share (%) Analysis 2021 & 2031, By Region
Figure 15: Global Hypoparathyroidism Treatment Market Y-o-Y Growth (%) Analysis 2019-2030, By Region
Figure 16: Global Hypoparathyroidism Treatment Market Attractiveness Analysis 2021–2031, By Region
Figure 17: North America Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 18: North America Hypoparathyroidism Treatment Market Forecast & Y-o-Y growth, 2021–2031
Figure 19: North America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Product Type
Figure 20: North America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Route of Administration
Figure 21: North America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 22: North America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 23: Latin America Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 24: Latin America Hypoparathyroidism Treatment Market Forecast & Y-o-Y growth, 2021–2031
Figure 25: Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Product Type
Figure 26: Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Route of Administration
Figure 27: Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 28: Latin America Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 29: Europe Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 30: Europe Hypoparathyroidism Treatment Market Forecast & Y-o-Y growth, 2021–2031
Figure 31: Europe Hypoparathyroidism Treatment Market Attractiveness Analysis, By Product Type
Figure 32: Europe Hypoparathyroidism Treatment Market Attractiveness Analysis, By Route of Administration
Figure 33: Europe Hypoparathyroidism Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 34: Europe Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 35: Asia Pacific Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 36: Asia Pacific Hypoparathyroidism Treatment Market Forecast & Y-o-Y growth, 2021–2031
Figure 37: Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis, By Product Type
Figure 38: Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis, By Route of Administration
Figure 39 Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 40: Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 41: Oceania Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 42: Middle East and Africa Hypoparathyroidism Treatment Market Value Analysis, 2016–2020
Figure 43: Middle East and Africa Hypoparathyroidism Treatment Market Forecast & Y-o-Y growth, 2021–2031
Figure 44: Middle East and Africa Hypoparathyroidism Treatment Market Attractiveness Analysis, By Product Type
Figure 45: Middle East and Africa Hypoparathyroidism Treatment Market Attractiveness Analysis, By Route of Administration
Figure 46: Middle East and Africa Hypoparathyroidism Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 47: Middle East and Africa Hypoparathyroidism Treatment Market Attractiveness Analysis, By Country
Figure 48: U.S. Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 49: U.S. Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 50: U.S. Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 51: Canada Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 52: Canada Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 53: Canada Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 54: Mexico Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 55: Mexico Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 56: Mexico Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 57: Brazil Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 58: Brazil Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 59: Brazil Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 60: U.K. Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 61: U.K. Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 62: U.K. Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 63: Germany Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 64: Germany Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 65: Germany Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 66: France Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 67: France Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 68: France Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 69: France Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021E
Figure 70: Italy Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 71: Italy Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 72: Italy Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 73: Spain Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 74: Spain Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 75: Spain Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 76: Spain Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021
Figure 77: China Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 78: China Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 79: China Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 80: China Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021
Figure 81: Japan Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 82: Japan Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 83: Japan Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 84: Japan Hypoparathyroidism Treatment Market Share Analysis (%), By End-user, 2021E
Figure 85: India Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 86: India Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 87: India Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 88: India Hypoparathyroidism Treatment Market Share Analysis (%), Distribution Channel, 2021
Figure 89: Australia & New Zealand Hypoparathyroidism Treatment Market Share Analysis (%) 2021E & 2031F
Figure 90 Australia & New Zealand Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 91: Australia & New Zealand Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 92: Australia & New Zealand Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021E
Figure 93: GCC Countries Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 94: GCC Countries Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 95: GCC Countries Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 96: GCC Countries Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021E
Figure 97: South Africa Hypoparathyroidism Treatment Market Share Analysis (%), 2021E & 2031F
Figure 98: South Africa Hypoparathyroidism Treatment Market Share Analysis (%), By Product Type, 2021E
Figure 99: South Africa Hypoparathyroidism Treatment Market Share Analysis (%), By Route of Administration, 2021E
Figure 100: South Africa Hypoparathyroidism Treatment Market Share Analysis (%), By Distribution Channel, 2021E
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
